Drug Shortage Report for TEVA-BUDESONIDE

Last updated on 2023-10-06 History
Report ID 167197
Drug Identification Number 02465949
Brand name TEVA-BUDESONIDE
Common or Proper name BUDESONIDE
Company Name TEVA CANADA LIMITED
Market Status MARKETED
Active Ingredient(s) BUDESONIDE
Strength(s) 0.125MG
Dosage form(s) SUSPENSION
Route of administration INHALATION INHALATION
Packaging size 2
ATC code R03BA
ATC description OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2022-08-18
Estimated end date 2023-11-10
Actual end date 2023-10-05
Shortage status Resolved
Updated date 2023-10-06
Company comments
Health Canada comments
Tier 3 Status No
Contact Address 30 NOVOPHARM COURT
TORONTO, ONTARIO
CANADA M1B 2K9
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v34 2023-10-06 French Compare
v33 2023-10-06 English Compare
v32 2023-10-05 French Compare
v31 2023-10-05 English Compare
v30 2023-10-04 French Compare
v29 2023-10-04 English Compare
v28 2023-08-17 French Compare
v27 2023-08-17 English Compare
v26 2023-07-27 French Compare
v25 2023-07-27 English Compare
v24 2023-07-19 French Compare
v23 2023-07-19 French Compare
v22 2023-07-19 English Compare
v21 2023-06-08 French Compare
v20 2023-06-08 English Compare
v19 2023-06-08 French Compare
v18 2023-06-08 English Compare
v17 2023-04-27 French Compare
v16 2023-04-27 English Compare
v15 2023-01-19 French Compare

Showing 1 to 20 of 34